Quality-of-life effects of prostate-specific antigen screening

New England Journal of Medicine

Volumn 367, Issue 7, 2012, Pages 595-605

  Heijnsdijk, Eveline A M ^a   Wever, Elisabeth M ^a   Auvinen, Anssi ^c,f   Hugosson, Jonas ^h   Ciatto, Stefano ^h,i   Nelen, Vera ^j   Kwiatkowski, Maciej ^k   Villers, Arnauld ^g   Páez, Alvaro ^l   Moss, Sue M ^m   Zappa, Marco ⁱ   Tammela, Teuvo L J ^d   Mäkinen, Tuukka ^e   Carlsson, Sigrid ⁿ   Korfage, Ida J ^a   Essink Bot, Marie Louise ^b   Otto, Suzie J ^a   Draisma, Gerrit ^a   Bangma, Chris H ^a   Roobol, Monique J ^a   Schröder, Fritz H ^a   De Koning, Harry J ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Institute for Cancer Prevention   (Italy)

^j Provinciaal Instituut voor Hygiene   (Belgium)

^k CANTONAL HOSPITAL AARAU   (Switzerland)

^l HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^m QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FOLLOW UP; HEALTH CARE PLANNING; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEADY STATE;

EID: 84865029404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1201637     Document Type: Article

References (54)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
2. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90.
3. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
4. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9. [Erratum, N Engl J Med 2009;360:1797.]
5. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78. (Pubitemid 36833878)
6. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
7. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008;64:10-9. (Pubitemid 351316858)
8. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998;9:1297-300. (Pubitemid 29045568)
9. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005;116:291-6. (Pubitemid 40967268)
10. Hugosson J, Aus G, Becker C, et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 2000;85:1078-84. (Pubitemid 30348803)
11. Crawford ED, Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73.
12. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 2007;18:279-85. (Pubitemid 46356208)
13. Roobol MJ, Schroder FH. European Randomized study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results. BJU Int 2003;92:Suppl 2:1-122.
14. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 2010;126:2387-93.
15. European standard population. Newport, United Kingdom: Office for National Statistics (http://www.statistics.gov.uk).
16. Institute for Clinical Research and Health Policy Studies. The Cost-Effectiveness Analysis Registry. Boston: Tufts Medical Center, Center for the Evaluation of Value and Risk in Health (http://www.cearegistry.org).
17. Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schröder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998;90:925-31. (Pubitemid 28304162)
18. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer 1991;49:538-44.
19. Korfage IJ, de Koning HJ, Roobol M, Schröder FH, Essink-Bot ML. Prostate cancer diagnosis: the impact on patients' mental health. Eur J Cancer 2006;42:165-70. (Pubitemid 43083485)
20. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care 2005;43:347-55. (Pubitemid 40515624)
21. Konski A, Sherman E, Krahn M, et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys 2005;63:788-94. (Pubitemid 41400067)
22. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61. (Pubitemid 351439226)
23. Calvert NW, Morgan AB, Catto JW, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003;88:31-5. (Pubitemid 36241214)
24. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer 1996;77:1854-61.
25. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005;118:850-7. (Pubitemid 41097462)
26. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669-76.
27. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007;52:1560-3. (Pubitemid 350052404)
28. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010;304:2373-80. [Erratum, JAMA 2011;305:1862.]
29. Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G. Long-term hormone therapy and radiation is costeffective for patients with locally advanced prostate carcinoma. Cancer 2006;106:51-7. (Pubitemid 43032548)
30. Moeremans K, Caekelbergh K, Annemans L. Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer. Value Health 2004;7:472-81. (Pubitemid 39038456)
31. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol 2005;174:547-52. (Pubitemid 40981597)
32. Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 2005;66:835-9. (Pubitemid 41440834)
33. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-21. (Pubitemid 351671887)
34. Prostate cancer incidence and mortality rates. Utrecht, the Netherlands: Comprehensive Cancer Centers (http://www.ikcnet.nl).
35. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
36. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101. (Pubitemid 40617061)
37. Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-54.
38. Roobol MJ, Kerkhof M, Schröder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009;56:584-91.
39. Carlsson S, Aus G, Bergdahl S, et al. The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. Eur J Cancer 2011;47:545-53.
40. Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
41. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007;177:107-12. (Pubitemid 44879468)
42. Stattin P, Holmberg E, Bratt O, et al. Surveillance and deferred treatment for localized prostate cancer: population based study in the National Prostate Cancer Register of Sweden. J Urol 2008;180:2423-9.
43. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
44. Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011;12:891-9.
45. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 2009;339:b4817.
46. Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML. Patients' perceptions of the side-effects of prostate cancer treatment - a qualitative interview study. Soc Sci Med 2006;63:911-9.
47. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19:1619-28. (Pubitemid 32230861)
48. Mols F, Korfage IJ, Vingerhoets AJ, et al. Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study. Int J Radiat Oncol Biol Phys 2009;73:30-8.
49. Thong MS, Mols F, Kil PJ, Korfage IJ, van de Poll-Franse LV. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int 2010;105:652-8.
50. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004;96:1358-67. (Pubitemid 39406169)
51. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009;27:3916-22.
52. Auvinen A, Raitanen J, Moss S, et al. Test sensitivity in the European Prostate Cancer Screening Trial: results from Finland, Sweden, and the Netherlands. Cancer Epidemiol Biomarkers Prev 2009;18:2000-5.
53. Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011;117:2883-91.
54. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010;116:5226-34. [Erratum, Cancer 2011;117:2825.]